Tapentadol for pain: A treatment evaluation

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 283-286

  Hartrick, Craig T ^a,b   Rodríguez Hernandez, Jose Rafael ^c  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c Neuro Psychiatric and Pain Management Institute   (Puerto Rico)

Author keywords

Analgesia; Clinical use; Dual mechanism; MOR NRI; Norepinephrine reuptake inhibition; Opioid agonist; Tapentadol

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; TAPENTADOL; TRAMADOL;

ANALGESIA; ARTICLE; CHRONIC PAIN; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALGESIA; LOW BACK PAIN; NAUSEA; NEUROPATHIC PAIN; PAIN; PERIPHERAL NEUROPATHY; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; VOMITING;

ACUTE PAIN; ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, OPIOID; CHRONIC PAIN; HUMANS; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 84855863188     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.648616     Document Type: Article

References (20)

1. Hartrick CT, Rozek RJ. Tapentadol in pain management: a μ -opioid receptor agonist and norepinephrine reuptake inhibitor. CNS Drugs 2011;25(5):359-70
2. Hartrick CT. Tapentadol immediate release for the relief of moderate-to-severe pain. Expert Opin Pharmacother 2009;10(16):2687-96
3. Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficiacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008;107(6):2048-55
4. Stegmann JU, Weber H, Steup A, et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008;24(11):3185-96
5. Daniels SE, Umpalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25(3):765-76
6. Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009;25(6):1551-61
7. Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31(2):260-71
8. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30(8):489-505
9. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11(11):1787-804
10. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27(1):151-62
11. Tapentadol label. Available from: http://www.nucynta.com/sites/all/ themes/nucynta/pdf/Nucynta-PI.pdf [Accessed 2 November 2011]
12. Tapentadol ER label. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/200533s000lbl.pdf [Accessed 2 November 2011]
13. Hartrick CT. Tapentadol immediate-release for acute pain: a drug profile. Expert Rev Neurother 2010;10(6):861-9
14. Cepeda M, Sutton A, Weinstein R, Kim M. Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. Clin J Pain 2011; [Epub ahead of print]
15. Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011;27(10):1907-30
16. Kwong WJ, Ozer-Stillman I, Miller JD, et al. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin Ther 2010;32(10):1768-81
17. Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337(1):312-20
18. Pergolizzi J, Alegre C, Blake D, et al. Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pain Pract 2011; [Epub ahead of print]
19. Schroder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14(8):814-21
20. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10(5):416-27